Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Clinical trial NCT05915442 · RECRUITING

Trial details

NCT number: NCT05915442
Sponsor: Catherine Spina
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Oligometastatic Prostate Cancer

Start date: 2023-07-01
Primary completion: 2026-12-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.